Medisun Lifescience Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 05-01-2025
- Paid Up Capital ₹ 1.75 M
as on 05-01-2025
- Company Age 12 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.30 M
as on 05-01-2025
- Revenue -24.13%
(FY 2021)
- Profit -29.10%
(FY 2021)
- Ebitda -42.47%
(FY 2021)
- Net Worth 7.35%
(FY 2021)
- Total Assets -18.00%
(FY 2021)
About Medisun Lifescience
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 1.75 M.
The company currently has active open charges totaling ₹1.30 M.
Juhi Dhameliya, Rajeshri Pipaliya, Sonalben Savaliya, and Three other members serve as directors at the Company.
- CIN/LLPIN
U51909GJ2012PTC070243
- Company No.
070243
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 May 2012
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Surat, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Medisun Lifescience?
Board Members(6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Juhi Dhameliya  | Director | 08-May-2012 | Current |
| Rajeshri Pipaliya | Director | 08-May-2012 | Current |
| Sonalben Savaliya | Director | 25-May-2012 | Current |
| Amitaben Godhani | Director | 02-Jul-2012 | Current |
| Bhatrusha Sonani | Director | 02-Jul-2012 | Current |
| Deepika Lathiya | Director | 15-Feb-2014 | Current |
Financial Performance of Medisun Lifescience.
Medisun Lifescience Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 24.13% decrease. The company also saw a substantial fall in profitability, with a 29.1% decrease in profit. The company's net worth moved up by a moderate rise of 7.35%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Medisun Lifescience?
In 2023, Medisun Lifescience had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Candor Ivf Center And Research Institute Private LimitedActive 2 years 7 monthsJuhi Dhameliya is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 27 Apr 2016 | ₹1.30 M | Open |
How Many Employees Work at Medisun Lifescience?
Unlock and access historical data on people associated with Medisun Lifescience, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Medisun Lifescience, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Medisun Lifescience's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
